Over a Million Die from Tuberculosis Annually—It Doesn't Have to Be This Way
The author John Green highlights the devastating impact of policy changes on tuberculosis patients and explores how we can respond effectively.
Humanity's struggle with tuberculosis (TB) has been marked by gradual and challenging advancements. Although TB no longer ravages the United States like in the 1800s, it remains a grave threat globally. In 2023, TB claimed more than 1.2 million lives, once again likely becoming the most lethal infection worldwide, momentarily overshadowed by COVID-19 during the pandemic.
John Green, an author and public figure, recently commented that TB deaths are expected to increase soon. The cessation of funding for global TB initiatives as part of the US government's budget cuts has exacerbated this situation. As the US is the largest funder for TB treatment worldwide, these financial cuts have endangered critical medical care for those suffering from TB. Delays in treatment can lead to more severe outcomes and contribute to antibiotic resistance.
Current Challenges and Global Impact
An alarming prediction suggests that by 2030, there could be an additional 10 million TB cases due to the curtailment of aid, potentially resulting in 2.2 million more deaths if cuts continue. The uncertainty on the ground complicates matters, as legal battles aim to restore aid and government communications have been inconsistent. For instance, a TB program representative noted that funding had yet to resume, despite assurances to the contrary.
The funding halt endangers not only those in developing countries but also poses a significant threat to the US itself. Kansas, for example, reports 68 active TB cases, marking it as one of the largest outbreaks in recent US history. As TB cases rise globally, similar trends are anticipated within the US, pushing healthcare costs up and increasing the likelihood of drug-resistant TB strains that could have devastating effects both locally and internationally.
Historical Perspectives and Ongoing Stigma
Once thought to be a disease of the past, TB remains the deadliest infection today, affecting approximately 10 million individuals annually, with over a million fatalities. For many, TB is latent and doesn't manifest in immediate symptoms, a condition managed by the immune system forming protective tubercles. Yet, for a small fraction, these defenses fail, resulting in active disease.
There are known risk factors, such as malnutrition and concurrent illnesses like diabetes or HIV, but why some people develop active TB and others do not remains partially understood. A peculiar aspect of TB is its slow growth and the unique, thick, fatty cell wall of the bacteria, prolonging its incubation period and making it a slow, lingering threat.
TB's Changing Image and Racial Disparities
Historically, TB was glamorized, often being associated with poets and artists. However, after the discovery of its bacterial origins in 1882 by Robert Koch, it was re-imagined as a disease rooted in poverty. This shift led to societal stigmatization, with those afflicted often viewed as threats to public health.
Racial biases further skewed perceptions, with erroneous beliefs about susceptibility tied to race. These misconceptions persist to some degree, shaping both survival outcomes and access to care. Even with advances in TB treatment, broad disparities in the distribution of therapies have led to drug resistance and ongoing health challenges.
Call to Action: Bridging Gaps and Increasing Awareness
The regression in global health advancements, particularly concerning TB, highlights the need for sustained commitment and advocacy. It's vital to address the empathy and social justice gaps that separate privileged societies from those bearing the brunt of infectious diseases. By fostering a deeper understanding and empathy for those affected, more equitable outcomes can be achieved.
Individuals can contribute by voicing concerns to policymakers to reverse funding cuts and support consistent global health programs. Each of us can play a role in advocating for sustained global health initiatives, ensuring they reach those most in need and preventing the scale of future healthcare crises.




Leave a Reply